Dystrophie musculaire de Duchenne Dystrophie musculaire de Duchenne Dystrophie musculaire de Duchenne

Archives

Author Archive for: "Marie"
The global day of giving
By Marie
In Fundraising
Posted 9 November 2021

The global day of giving

Giving Tuesday – the global day of giving After Black Friday and Cyber Monday, imagine a day dedicated to giving back, around the world, across Canada and in our community. Black Friday kicks off [...]

EMBARK, gene therapy for the treatment of DMD
By Marie
In News, Research, Treatments
Posted 4 October 2021

EMBARK, gene therapy for the treatment of DMD

Sarepta Therapeutics announces initiation of EMBARK, a global p0ivotal study of SRP-9001, gene therapy for the treatment of DMD (Duchenne Muscular Dystrophy) Original press release > [...]

Part B of MOMENTUM study of SRP-5051 in patients with DMD
By Marie
In Research, Treatments
Posted 27 September 2021

Part B of MOMENTUM study of SRP-5051 in patients with DMD

Sarepta Therapeutics to initiate Part B of MOMENTUM study of SRP-5051 in patients with Duchenne muscular dystrophy (DMD) amenable to Exon 51 skipping following positive interactions with FDA [...]

World Duchenne Awareness Day 2021
By Marie
In in the Medias
Posted 31 August 2021

World Duchenne Awareness Day 2021

September 7 is World Duchenne Awareness Day. On this day, we raise awareness for Duchenne and Becker muscular dystrophy (DMD and BMD) around the globe. An initiative coordinated by the World [...]

ENDEAVOR, gene therapy for DMD
By Marie
In News, Research, Treatments
Posted 20 May 2021

ENDEAVOR, gene therapy for DMD

Sarepta Therapeutics’ investigational gene therapy for the treatment of Duchenne muscular dystrophy, SRP-9001, demonstrates robust expression and consistent safety profile using Sarepta’s [...]

Positive clinical results from phase 2 MOMENTUM study
By Marie
In News, Research, Treatments
Posted 4 May 2021

Positive clinical results from phase 2 MOMENTUM study

Sarepta Therapeutics reports positive clinical results from phase 2 MOMENTUM study of SRP-5051 in patients with Duchenne muscular dystrophy amenable to skipping exon 51 Results suggest a highly [...]

Genethon announces First Patient dosed in Clinical Trial
By Marie
In Research
Posted 20 April 2021

Genethon announces First Patient dosed in Clinical Trial

Genethon announces First Patient dosed in Clinical Trial of Investigational Gene therapy GNT004 for Duchenne Muscular Dystrophy. Communiqué de presse original > Genethon   A first [...]

Pamrevlumab for the treatment of DMD
By Marie
In Research
Posted 13 April 2021

Pamrevlumab for the treatment of DMD

FibroGen receives Fast Track designation from the U.S. FDA for Pamrevlumab to treat Duchenne muscular dystrophy (DMD). April 12, 2021, Original press release. Source: FibroGen, Inc   [...]

Solid Biosciences reports efficacy and safety data
By Marie
In Research
Posted 24 March 2021

Solid Biosciences reports efficacy and safety data

Solid Biosciences reports efficacy and safety data from the ongoing IGNITE DMD clinical trial and resumption of patient dosing in the 2E14 VG/kg cohort. La Force is sharing this press release [...]

Article about DMD in Nature.com
By Marie
In in the Medias
Posted 16 March 2021

Article about DMD in Nature.com

Recent studies on Duchenne muscular dystrophy (DMD) have greatly deepened our understanding of the primary and secondary pathogenetic mechanisms. Guidelines for the multidisciplinary care for DMD [...]

1 2 3 4 5 6 7 8 9 ...
page 1 of 13

Articles récents

  • The global day of giving
  • EMBARK, gene therapy for the treatment of DMD
  • Part B of MOMENTUM study of SRP-5051 in patients with DMD
  • World Duchenne Awareness Day 2021
  • ENDEAVOR, gene therapy for DMD

Catégories

  • Fundraising
  • in the Medias
  • News
  • Research
  • Testimonial
  • Treatments

+

Restez informé

    LA Force - Dystrophie musculaire de Duchenne

    La Force dmd - Tous droits réservés - Organisme de bienfaisance enregistré : 817683568RP0001
    La Force dmd La Force dmd
    • S’informer
      • Frequently Asked Questions
    • Make a Donation
    • Agir
      • Quick guige – Management of DMD
      • Take action – What’s your genetic profile?
      • Take action – Subscribe to registries
    • Aller plus loin
      • Go further – How can you access a new treatment?
      • Go further – How do researchers test new treatments?
      • Go further – How are drugs approved for use in Canada?
      • Go further – Who decides to reimburse drug costs?
    • Blog
    • About us
    • Contact-us
    Manage Cookie Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistiques
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
    View preferences
    {title} {title} {title}